Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended July 31, 2004
Business Overview: Cooper operates two primary business units: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended July 31, 2004 |
9 Months Ended July 31, 2004 |
|---|---|---|
| Net Sales | $129,079 | $359,365 |
| Gross Profit | $83,134 | $231,475 |
| Gross Margin | 64% | 64% |
| Operating Income | $31,668 | $84,340 |
| Net Income | $24,048 | $64,102 |
| Diluted EPS | $0.70 | $1.89 |
| Cash from Operations (9mo) | $65,963 | |
| Total Debt | $170,428 | |
| Cash & Equivalents | $26,075 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% in the quarter and 20% year-to-date compared to the prior year periods. CooperVision (CVI) sales grew 17% (quarter) and 19% (9 months), while CooperSurgical (CSI) sales grew 27% (quarter) and 24% (9 months).
- Profitability: Operating income rose 25% in the quarter and 27% year-to-date. Net income increased 29% in the quarter and 34% year-to-date.
- Acquisitions: Significant revenue growth in CSI was driven by recent acquisitions (Milex, Argus, Opti-Centre). CVI growth was driven by market share gains in specialty lenses (toric, multifocal) and the global rollout of Proclear products.
- Expenses: Selling, general, and administrative (SGA) expenses increased 18% in the quarter, partly due to foreign currency weakness and new sales programs at CSI. Research and development expenses increased 30% in the quarter.
- Tax Rate: The effective tax rate for the quarter was 19%, down from 22% in the prior year, due to a release of tax accruals and a shift of income to lower-tax jurisdictions.
Guidance, Outlook, and Risks
- Proposed Acquisition: On July 28, 2004, Cooper signed a definitive agreement to acquire Ocular Sciences, Inc. for approximately $1.2 billion (cash and stock). The transaction is subject to regulatory approval (FTC issued a Second Request for Information) and shareholder approval.
- Capital Expenditures: Management expects fiscal year 2004 capital expenditures to be between $40 million and $45 million, primarily to double U.K. manufacturing capacity.
- Liquidity: The company maintains $143.1 million in available credit under its KeyBank facility. Management believes current cash and operating cash flow will fund operations and smaller acquisitions, excluding the Ocular merger.
- Risks: Key risks include the inability to obtain regulatory approval for the Ocular merger, integration challenges, foreign currency exchange exposure, and potential changes in accounting standards regarding convertible debt and stock-based compensation.
- Convertible Debt: The company issued $115 million in 2.625% convertible senior debentures. Dilution from these instruments may impact future earnings per share calculations depending on final FASB rulings.
Investor Verification Checklist
- Ocular Sciences Merger Status: Verify the outcome of the FTC Second Request and the timeline for closing the $1.2 billion acquisition.
- Convertible Debt Impact: Monitor FASB rulings on EITF Issue 04-8 regarding the treatment of contingently convertible debt in diluted EPS calculations.
- Acquisition Integration: Assess the financial performance and integration progress of recent CSI acquisitions (Milex, Argus, Opti-Centre) to ensure organic growth targets are met.
- Foreign Currency Exposure: Review the impact of currency fluctuations on the U.K. manufacturing costs and international revenue, given the significant portion of operations outside the U.S.
- Inventory Levels: Confirm that inventory increases (up $15.4 million year-to-date) align with sales growth and do not indicate obsolescence risks.